May 03, 2021
Baricitinib in combination with Remdesivir, is used for treatment of Covid positive patients.
Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets from Central Drugs Standard Control Organization (CDSCO) in India.
Baricitinib in combination with Remdesivir, is used for treatment of Covid-19 positive patients.
Hyderabad-based Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic.
The company is ready to launch the product this week, so as to make it available to suffering patients across India, the release added.
(2)
INDIANAPOLIS (dpa-AFX) - Today s Daily Dose brings you news about KalVista s hereditary angioedema trial results, Heat Biologics encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamida s presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance.
Read on.
1. Gamida s Presentation At TCT Meetings Catches Eyes
Shares of Gamida Cell Ltd. (GMDA) were up over 60% at $16 in extended trading Tuesday, following the presentation of full efficacy and safety results of the company s phase III clinical trial of Omidubicel in patients with hematologic malignancies undergoing a bone marrow transplant at the 2021 TCT Meetings.